References: Essential thrombocythemia and polycythemia vera

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*. 2009;114(5):937-951.

2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia*. 2008;22(1):14-22.

3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia*. 2010;24(6):1128-1138.

4. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. *Leukemia*. 2007;21(9):1960-1963.

5. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. *Leukemia*. 2008;22(7):1299-1307.

6. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. *Am J Hematol*. 2011;86(8):668-676. Prepublished on 2011/06/16 as DOI 10.1002/ajh.22063.

7. Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. *Am J Hematol*. 2011;86(8):701-702. Prepublished on 2011/06/16 as DOI 10.1002/ajh.22058.

8. Boyd EM, Bench AJ, Goday-Fernandez A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. *Br J Haematol*;149(2):250-257.

9. Ohashi H, Arita K, Fukami S, et al. Two rare MPL gene mutations in patients with essential thrombocythemia. *Int J Hematol*. 2009;90(3):431-432.

10. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood*. 2008;112(1):141-149.

11. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. *Blood*. 2004;103(11):4198-4200.

12. Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. *Haematologica*. 2009;94(10):1368-1374.

13. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. *The New England journal of medicine*. 2012;366(10):967-969. Prepublished on 2012/03/09 as DOI 10.1056/NEJMc1200349.

14. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood*. 2006;108(10):3472-3476.

15. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. *Blood*. 2008;112(3):844-847.

16. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. *Br J Haematol*. 2007;137(3):244-247.

17. Hussein K, Bock O, Theophile K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. *Leukemia*. 2009;23(5):852-855.

18. Hussein K, Theophile K, Buhr T, Beller A, Kreipe H, Bock O. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation. *Br J Haematol*. 2009;145(5):673-675. Prepublished on 2009/04/07 as DOI BJH7671 [pii]
10.1111/j.1365-2141.2009.07671.x.
19. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. *Haematologica*. 2008;93(1):34-40.
20. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK*. 2011;25(7):1217-1219. Prepublished on 2011/05/04 as DOI 10.1038/leu.2011.77.
21. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK*. 2009;23(11):2183-2186. Prepublished on 2009/07/18 as DOI 10.1038/leu.2009.141.
22. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. *Leukemia*. 2010;24(9):1574-1579.
23. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol*. 2011;29(23):3179-3184. Prepublished on 2011/07/13 as DOI JCO.2010.34.5298 [pii]
10.1200/JCO.2010.34.5298.
24. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. *Blood*. 2011;117(22):5857-5859. Prepublished on 2011/04/15 as DOI blood-2011-02-339002 [pii]
10.1182/blood-2011-02-339002.
25. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. *Blood*. 2011;117(10):2813-2816. Prepublished on 2011/01/13 as DOI blood-2010-11-316810 [pii]
10.1182/blood-2010-11-316810.
26. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. *Leukemia*. 2011;25(12):1834-1839. Prepublished on 2011/06/22 as DOI 10.1038/leu.2011.161
leu2011161 [pii].
27. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood*. 2007;110(4):1092-1097.
28. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. *Br J Haematol*. 2005;131(2):166-171.
29. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. *Leukemia*. 2006;20(2):350-353.
30. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. *Haematologica*. 2004;89(10):1194-1198.

31. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. *Br J Haematol*. 2005;131(2):208-213.
32. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. *J Clin Oncol*. 2009;27(34):e220-221; author reply e222-223.
33. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. *Am J Hematol*. 2010;85(1):62-69.
34. Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. *Ann Hematol*. 2004;83(8):504-512.
35. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. *Leukemia*. 2008;22(2):437-438.
36. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. *Leukemia*. 2008;22(8):1494-1502.
37. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. *Haematologica*. 2008;93(11):1645-1651.
38. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. *Am J Med*. 2004;117(10):755-761.
39. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. *Br J Haematol*. 2007;138(3):354-358.
40. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. *Br J Haematol*. 2007;136(2):249-259.
41. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. *Blood*. 1984;64(5):981-985.
42. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. *Leukemia*. 2007;21(2):270-276.
43. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. *British Journal of Haematology*. 2013;160(2):251-254. Prepublished on 2012/11/16 as DOI 10.1111/bjh.12117.
44. Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. *Am J Hematol*. 2009;85(2):93-94.
45. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? *Blood*. 2009;114(4):759-763.
46. Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. *Am J Hematol*. 2009;84(10):629-630.

47. Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. *J Thromb Haemost.* 2010;8(2):411-413.
48. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. *Eur J Haematol.* 2009;82(5):350-353.
49. Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. *Ann Hematol.* 2010;89(7):691-699.
50. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. *Semin Thromb Hemost.* 2007;33(4):313-320.
51. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. *Br J Haematol.* 2001;115(3):619-621.
52. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. *Semin Thromb Hemost.* 2006;32(6):589-604.
53. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med.* 2004;350(2):114-124.
54. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. *Blood.* 2010;116(8):1205-1210; quiz 1387.
55. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *The New England journal of medicine.* 2013;368(1):22-33. Prepublished on 2012/12/12 as DOI 10.1056/NEJMoa1208500.
56. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. *Acta Med Scand.* 1962;172:513-523.
57. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. *Platelets.* 2006;17(8):528-544.
58. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. *Annals of Internal Medicine.* 1985;102(4):466-471.
59. van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. *Thrombosis & Haemostasis.* 1996;76(3):333-338.
60. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. *Thrombosis & Haemostasis.* 1995;73(2):210-214.
61. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood.* 2012;119(15):3595-3603. Prepublished on 2012/01/12 as DOI 10.1182/blood-2011-06-359224.
62. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. *Eur J Haematol.* 2004;73(6):431-436.

63. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. *Eur J Haematol*. 2001;66(3):152-159.
64. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. *Blood*. 2007;110(2):485-489.
65. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. *Semin Thromb Hemost*. 2006;32(4 Pt 2):422-429.
66. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. *Best Pract Res Clin Haematol*. 2003;16(2):227-242.
67. Vaa BE, Wolanskyj AP, Roeker L, et al. Pruritus in primary myelofibrosis: Clinical and laboratory correlates. *Am J Hematol*. 2011. Prepublished on 2011/11/15 as DOI 10.1002/ajh.22215.
68. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. *Blood*. 2002;99(7):2627.
69. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. *Leukemia*. 2011;25(2):218-225. Prepublished on 2010/11/17 as DOI leu2010269 [pii] 10.1038/leu.2010.269.
70. Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. *British Journal of Haematology*. 1995;89(2):313-318.
71. Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. *Br J Dermatol*. 2002;147(5):979-981.
72. Kayacioglu I, Gunay R, Saskin H, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. *Heart Surg Forum*. 2008;11(3):E152-157.
73. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med*. 2005;353(1):33-45.
74. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. *J Clin Oncol*. 2011;29(7):789-796. Prepublished on 2011/01/12 as DOI JCO.2010.32.8021 [pii] 10.1200/JCO.2010.32.8021.
75. Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. *Blood*. 1986;68(6):1213-1217.
76. Lopez-Fernandez MF, Lopez-Berges C, Martin R, Pardo A, Ramos FJ, Batlle J. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. *Thromb Haemost*. 1987;58(2):753-757.
77. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. *Blood*. 1996;87(10):4235-4244.
78. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature*. 2001;413(6855):488-494.

79. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. *Bailliere's Best Practice in Clinical Haematology*. 2001;14(2):401-436.
80. van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. *Br J Haematol*. 1996;93(4):962-965.
81. van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. *Br J Haematol*. 1997;99(4):832-836.
82. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. *Thromb Haemost*. 2000;83(1):127-135.
83. Wehmeier A, Fricke S, Scharf RE, Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. *European Journal of Haematology*. 1990;45(4):191-197.
84. Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. *Haemostasis*. 1989;19(5):251-259.
85. Gersuk GM, Carmel R, Pattengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. *Blood*. 1989;74(7):2330-2334.
86. Burstein SA, Malpass TW, Yee E, et al. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. *British Journal of Haematology*. 1984;57(3):383-392.
87. Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. *Thrombosis Research*. 1991;61(3):271-278.
88. Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. *New England Journal of Medicine*. 1978;299(10):505-509.
89. Mazzucato M, De Marco L, De Angelis V, De Roia D, Bizzaro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. *British Journal of Haematology*. 1989;73(3):369-374.
90. Le Blanc K, Lindahl T, Rosendahl K, Samuelsson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. *Thrombosis Research*. 1998;91(6):287-295.
91. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.[see comment]. *British Journal of Haematology*. 2000;110(1):116-124.
92. Tefferi A, Smock KJ, Divgi AB. Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. *Am J Hematol*. 2010;85(7):545.
93. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med*. 1981;304(8):441-447.
94. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group. In:

Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: W.B. Saunders; 1995:166--194.
95. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). *Br J Cancer*. 1981;44(1):75-80.
96. Najean Y, Rain JD. Treatment of Polycythemia Vera - the Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years. *Blood*. 1997;90(9):3370-3377.
97. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. *J Clin Oncol*. 2011;29(29):3907-3913. Prepublished on 2011/09/14 as DOI JCO.2011.36.0792 [pii] 10.1200/JCO.2011.36.0792.
98. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. *Blood*. 1997;89(7):2319-2327.
99. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. *Seminars in Hematology*. 1986;23(3):172-176.
100. Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). *Pathol Biol (Paris)*. 2004;52(5):285-288.
101. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *N Engl J Med*. 1995;332(17):1132-1136.
102. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. *Blood*. 2013. Prepublished on 2013/01/15 as DOI 10.1182/blood-2012-07-443770.
103. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From Efficacy to Safety - a Polycythemia Vera Study Group Report On Hydroxyurea in Patients With Polycythemia Vera. *Seminars in Hematology*. 1997;34(1):17-23.
104. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. *Southern Medical Journal*. 1987;80(3):323-327.
105. Tatarsky I, Sharon R. Management of Polycythemia Vera With Hydroxyurea. *Seminars in Hematology*. 1997;34(1):24-28.
106. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. *Blood*. 2005;105:2664-2670.
107. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. *Haematologica*. 2000;85(10):1011-1018.
108. Petti MC, Spadea A, Avvisati G, et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). *Leukemia*. 1998;12(6):869-874.
109. De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. *Br J Haematol*. 2003;123(3):517-521.
110. Passamonti F, Rumi E, Malabarba L, et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. *Ann Hematol*. 2004;83(8):495-497.

111. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. *Br J Haematol*. 1985;61(4):657-666.
112. D'Emilio A, Battista R, Dini E. Treatment of primary proliferative polycythaemia by venesection and busulphan. *Br J Haematol*. 1987;65(1):121-122.
113. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. *Blood*. 1998;91(2):616-622.
114. Shvidel L, Sigler E, Haran M, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. *Leukemia*. 2007;21(9):2071-2072.
115. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. *Leukemia*. 2008;22(11):1990-1998.
116. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. *J Clin Oncol*. 2009;27(32):5418-5424.
117. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood*. 2008;112(8):3065-3072.
118. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). *Blood*. 2010;115(12):2354-2363.
119. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica*. 2005;90(8):1128-1132.
120. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. *Br J Haematol*. 1979;43(2):185-190.

References: Myelofibrosis

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia*. 2008;22(1):14-22.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia*. 2010;24(6):1128-1138.
3. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. *Leukemia*. 2011;25(7):1200-1202. Prepublished on 2011/04/02 as DOI 10.1038/leu.2011.58
leu201158 [pii].
4. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. *N Engl J Med*. 2011;364(5):488-490. Prepublished on 2011/02/04 as DOI 10.1056/NEJMc1012718.

5. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. *Blood*. 2012;120(20):4168-4171. Prepublished on 2012/09/13 as DOI 10.1182/blood-2012-05-429696.
6. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. *Leukemia*. 2007;21(9):1960-1963.
7. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. *N Engl J Med*. 2010;363(12):1189-1190.
8. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. *J Clin Oncol*. 2005;23(33):8520-8530.
9. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. *J Clin Oncol*. 2011;29(10):1356-1363. Prepublished on 2011/02/09 as DOI JCO.2010.32.9490 [pii] 10.1200/JCO.2010.32.9490.
10. Tefferi A. Myelofibrosis with Myeloid Metaplasia. *N Engl J Med*. 2000;342(17):1255-1265.
11. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood*. 2005;105(3):973-977.
12. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood*. 2007;110(4):1092-1097.
13. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. *Leukemia*. 2008;22(2):437-438.
14. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. *Am J Hematol*. 2010;85(1):62-69.
15. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. *Eur J Haematol*. 2009;82(5):329-338.
16. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol*. 2011;29(23):3179-3184. Prepublished on 2011/07/13 as DOI JCO.2010.34.5298 [pii] 10.1200/JCO.2010.34.5298.
17. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? *Leuk Res*. 2001;25(10):829-838.
18. Orazi A, O'Malley DP, Jiang J, et al. Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. *Mod Pathol*. 2005;18(5):603-614.
19. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood*. 2009;113(13):2895-2901.

20. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood*. 2010;115(9):1703-1708.
21. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. *Blood*. 2010;115(3):496-499.
22. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. *Leukemia*. 2011;25(1):82-88. Prepublished on 2010/10/15 as DOI leu2010234 [pii] 10.1038/leu.2010.234.
23. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. *Am J Hematol*. 2009;85(1):14-17.
24. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of International Prognostic Scoring System and Dynamic International Prognostic Scoring System. *Haematologica*. 2010.
25. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. *Eur J Haematol*. 2009.
26. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol*. 2011;29(4):392-397. Prepublished on 2010/12/15 as DOI JCO.2010.32.2446 [pii] 10.1200/JCO.2010.32.2446.
27. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. *Blood*. 2011;118(17):4595-4598. Prepublished on 2011/09/02 as DOI 10.1182/blood-2011-08-371096.
28. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. *Leukemia*. 2010;24(1):105-109.
29. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. *Leukemia*. 2008;22(4):756-761.
30. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. *Blood*. 2009;114(8):1477-1483.
31. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK*. 2012;26(3):475-480. Prepublished on 2011/09/14 as DOI 10.1038/leu.2011.253.
32. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. *Blood*. 2011;118(19):5227-5234. Prepublished on 2011/09/17 as DOI blood-2011-06-363424 [pii]

10.1182/blood-2011-06-363424.
33. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. *Genes, chromosomes & cancer*. 2012;51(8):743-755. Prepublished on 2012/04/11 as DOI 10.1002/gcc.21960.
34. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK*. 2011;25(12):1834-1839. Prepublished on 2011/06/22 as DOI 10.1038/leu.2011.161.
35. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. *Leukemia*. 2009;23(5):905-911.
36. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(10):1087-1094. Prepublished on 2012/02/15 as DOI 10.1200/JCO.2011.39.0310.
37. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(10):1356-1363. Prepublished on 2011/02/09 as DOI 10.1200/JCO.2010.32.9490.
38. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *J Clin Oncol*. 2009;27(33):5587-5593.
39. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. *Cancer*. 2008;112(12):2726-2732.
40. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. *Blood*. 2010;116(15):2857-2858.
41. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant*. 2010;16(3):358-367.
42. Silverstein MN. Agnogenic myeloid metaplasia. *Acton Mass, Publishing Science Group*. 1975:126.
43. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. *Cancer J*. 2007;13(6):377-383.
44. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. *Br J Haematol*. 2002;117(2):288-296.
45. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. *Cancer*. 2006;106(9):1974-1984.
46. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. *Blood*. 2003;101(7):2534-2541.
47. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood*. 2006;108(4):1158-1164.
48. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. *J Clin Oncol*. 2009;27(28):4760-4766.

49. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. *Eur J Haematol*. 2009;83(2):154-155.
50. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. *Leukemia*. 2007;21(8):1827-1828.
51. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. *Ann Hematol*. 2010.
52. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. *Blood*. 2001;97(6):1896.
53. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. 2009;114(26):5264-5270.
54. Deeg HJ, Appelbaum FR. Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. *Blood*. 2011;117(26):7185. Prepublished on 2011/07/02 as DOI 117/26/7185 [pii] 10.1182/blood-2011-04-349142.
55. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. *Leukemia*. 2008;22(1):23-30.
56. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. *Br J Haematol*. 2010;150(4):446-455.
57. DeAngelo DJ, Spencer A, Fischer T, et al. Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis. *ASH Annual Meeting Abstracts*. 2009;114(22):2898-.
58. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. *J Clin Oncol*. 2009;27(27):4563-4569.
59. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK*. 2011;25(2):301-304. Prepublished on 2010/11/06 as DOI 10.1038/leu.2010.254.
60. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. *American Journal of Hematology*. 2010;85(2):129-130. Prepublished on 2010/01/07 as DOI 10.1002/ajh.21598.
61. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. *N Engl J Med*. 2010;363(12):1117-1127.
62. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. *The New England journal of medicine*. 2011;365(15):1455-1457. Prepublished on 2011/10/15 as DOI 10.1056/NEJMc1109555.
63. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. *Mayo Clinic proceedings Mayo Clinic*. 2011;86(12):1188-1191. Prepublished on 2011/10/29 as DOI 10.4065/mcp.2011.0518.
64. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *The New England journal of medicine*. 2012;366(9):799-807. Prepublished on 2012/03/02 as DOI 10.1056/NEJMoa1110557.

65. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *The New England journal of medicine*. 2012;366(9):787-798. Prepublished on 2012/03/02 as DOI 10.1056/NEJMoa1110556.
66. Tefferi A, Litzow M, Pardanani A. Long-term outcome of ruxolitinib therapy in myelofibrosis. *N Engl J Med*. 2011;in press.
67. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(7):789-796. Prepublished on 2011/01/12 as DOI 10.1200/JCO.2010.32.8021.
68. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *Blood*. 2010;115(6):1131-1136. Prepublished on 2009/12/17 as DOI 10.1182/blood-2009-10-246363.
69. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. *Blood*. 2011;118(8):2069-2076. Prepublished on 2011/07/05 as DOI 10.1182/blood-2011-01-330563.
70. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. *Blood*. 2000;95(7):2226-2233. Prepublished on 2000/03/25 as DOI.
71. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. *Cancer*. 2006;107(2):361-370.
72. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. *Blood*. 1998;91(10):3630-3636.
73. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. *British Journal of Haematology*. 1998;103(2):505-511. Prepublished on 1998/11/25 as DOI.
74. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. *Mayo Clinic proceedings Mayo Clinic*. 2003;78(10):1223-1233. Prepublished on 2003/10/09 as DOI 10.4065/78.10.1223.
75. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. *British Journal of Haematology*. 2002;118(3):813-816. Prepublished on 2002/08/16 as DOI.
76. Neben-Wittich MA, Brown PD, Tefferi A. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. *American Journal of Hematology*. 2010;85(10):808-810. Prepublished on 2010/08/28 as DOI 10.1002/ajh.21819.
77. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. *European Journal of Haematology*. 2010;85(3):192-199. Prepublished on 2010/06/10 as DOI 10.1111/j.1600-0609.2010.01480.x.
78. Feldman LS, Demyttenaere SV, Polyhronopoulos GN, Fried GM. Refining the selection criteria for laparoscopic versus open splenectomy for splenomegaly. *J Laparoendosc Adv Surg Tech A*. 2008;18(1):13-19.

79. Iwase K, Higaki J, Mikata S, et al. Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. *Surg Laparosc Endosc Percutan Tech*. 1999;9(3):197-202.
80. Hiatt JR, Gomes AS, Machleder HI. Massive splenomegaly. Superior results with a combined endovascular and operative approach. *Arch Surg*. 1990;125(10):1363-1367.
81. Hocking WG, Machleder HI, Golde DW. Splenic artery embolization prior to splenectomy in end-stage polycythemia vera. *Am J Hematol*. 1980;8(1):123-127.
82. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica*. 2005;90(8):1128-1132.
83. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. *Br J Haematol*. 1979;43(2):185-190.
84. Gangat N, Caramazza D, Vaidya R, et al. DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis that Incorporates Prognostic Information from Karyotype, Platelet Count and Transfusion Status. *Journal of Clinical Oncology*. 2010;in press.
85. Eriksson KA, Sigvaldason A, Lindholm A, Safai-Kutti S, Kutti J. Platelet activation in response to phlebotomy. An experimental study of healthy blood donors. *Acta Med Scand*. 1982;212(3):121-123. Prepublished on 1982/01/01 as DOI.